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Abstract
Psoriasis is a multifactorial skin disease characterized by epidermal hyperproliferation and chronic
inflammation, the most common form of which is psoriasis vulgaris (PsV). We present a genome-
wide association analysis of 2,339,118 SNPs in 472 psoriasis patients and 1,146 controls from
Germany, with follow-up of the 147 most significant SNPs in 2,746 PsV cases and 4,140 controls
from three independent replication panels. We identified an association at TRAF3IP2 on 6q21 and
genotyped two SNPs at this locus in two additional replication panels (the combined discovery
and replication panels consisted of 6,487 cases and 8,037 controls; combinded P = 2.36×10−10 for
rs13210247 and combined P = 1.24×10−16 for rs33980500). About 15% of psoriasis cases
develope psoriatic arthritis (PsA). A stratified analysis of our datasets including only PsA cases
(1,922 cases compared to 8,037 controls, P=4.57×10−12 for rs33980500) suggested that
TRAF3IP2 represents a shared susceptibility for PsV and PsA. TRAF3IP2 encodes a protein
involved in IL-17 signaling and which interacts with memebers of the Rel/NF-κB transcription
factor family.
Psoriasis (MIM 177900) is a chronic immune-mediated and hyperproliferative disorder of
the skin that affects up to 3% of individual in populations of European ancestry1–3. The most
common form, PsV, is characterized by red, raised, scaly plaques that commonly occur on
the elbows, knees, scalp and lower back4.
Disease concordance in monozygotic twin pairs amounts to at most 70%5 and the sibling
recurrence risk, λs, of PsV has been estimated to range between 4 and 115,6. Part of the
genetic susceptibility can be explained by the established susceptibility locus at PSORS1 in
the human leucocyte antigen (HLA) complex on chromosome 6p21.3 (HLA-C) as well as
polymorphisms at the IL12B7, IL23R8–11, IL4/IL1312, IL23A, TNIP1 and TNFAIP313 loci.
Because these susceptibility loci only account for a λs of less than 1.3513, a large fraction of
the heritability for PsV remains unexplained. In addition, a deletion of two LCE cluster
genes has been proposed to be a risk factor for the development of psoriasis, implying that
structural variants could also contribute to the overall disease susceptibility14.
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To identify additional PsV susceptibility loci, we performed genome-wide SNP genotyping
of 487 German PsV cases and 1161 controls (screening panel A, Supplementary Table 1)
using the Illumina HumanHap 550k array. For genotype imputation with phased HapMap
data as a reference and subsequent statistical analysis, we used a data set that passed
stringent quality control filters. This cleaned data set consisted of 504,742 autosomal SNPs
genotyped in 472 cases and 1146 controls. Imputation served to considerably increase the
genomic coverage of our study to a total number of 2,339,118 SNPs. Conservatively
accounting for multiple testing by Bonferroni correction, the threshold for genome-wide
significance was P≤2.14×10−8 in the imputed data set. A moderate genomic control value of
λGC=1.065 indicated a minimal overall inflation of the test statistics due to population
stratification. Furthermore, the multidimensional scaling analysis showed genuine European
ancestry of panel A and identity-by-state analysis revealed neither non-European “outliers”
nor cryptically related individuals after quality control (Supplementary Fig. 1). Our
screening panel A had 80% power to detect a variant with an odds ratio of 1.38 or higher at
the 5% significance level, assuming a frequency of the disease-associated allele of at least
30% in controls.
The initial comparison of case-control frequencies confirmed the association of PsV with the
established susceptibility loci at HLA-C (rs12191877, P=4.21×10−32, OR=2.79, 95%
CI=2.35–3.33) and IL12B (rs2546890, P=8.83×10−8, OR=0.65, 95% CI=0.56–0.76).
Suggestive evidence for association was found for IL23R (rs1004819, P=6.17×10−4,
OR=1.33, 95% CI=1.13–1.57) and on 1q21, 22 kb upstream of LCE3C (rs4112788,
P=6.36×10−4, OR=0.76, 95% CI=0.64–0.89) (see Supplementary Fig. 2). The lead SNPs
rs2546890 and rs1004819 were in moderate linkage disequilibrium (LD) (r2>0.50) with the
previously described associated variants at the IL12B (rs7709212)9,15 and IL23R
(rs2201841)13 loci, respectively. To identify novel susceptibility loci, we excluded all SNPs
within the extended HLA complex (chromosome 6p21 at 25–34 Mb) and visually inspected
the cluster plots of all index SNPs with a P value less than 0.001 after the clumping
procedure. The 180 most strongly associated SNPs were subsequently selected for
replication analysis and genotyped in the German replication panel B (681 cases, 1824
controls). After quality control, we excluded 33 follow-up SNPs.
In addition, an in silico replication was performed using available genome-wide association
study (GWAS) datasets for panel C from the United States (1,303 cases and 1,322 controls;
Collaborative Association Study of Psoriasis (CASP))13 and for panel D form Canada (762
cases and 994 controls; S.D., J.V.R., M.B., H.F. and C.R., unpublished data). We imputed
both datasets, that is, the CASP dataset, which was genotyped by Perlegen Sciences, and the
Canadian dataset, which was generated using the Illumina Human 1M BeadChip, were
imputed. Of the 147 SNPs genotyped in panel B, we obtained genotypes for 126 SNPs in
panel C and for 144 SNPs in panel D. Detailed association results including genotype counts
of the 147 SNPs are given in Supplementary Table 2.
Two SNPs upstream of IL12B, included as a positive control for our experiment, achieved
genome-wide significance in the combined replication panels B through D (rs2546890:
replication stage P=9.07×10−15; rs953861: replication stage P=6.50×10−14). A previously
unidentified association in the combined analysis of the three replication panels was
obtained for SNP rs13210247 (replication stage P=6.25×10−6, risk allele frequency for cases
= 0.09, risk allele frequency for controls = 0.07) with association robust to Bonferroni
correction (corrected significance threshold of α=3.4×10−4, calculated as 0.05/147). This
intronic SNP is located in the TRAF3IP2 gene, which encodes the TRAF3 interacting
protein 2, and which is also known as ACT1, the NF- κB activator 1 protein. In the
combined panels A to D, consisting of a total of 3218 PsV cases and 5286 controls, this SNP
achieved genome-wide significance (Pcomb.=7.31×10−9) (Fig. 1). We observed suggestive
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evidence for association for four other SNPs; however, these associations did not remain
significant after Bonferroni correcting for multiple testing. These four SNPs are located in
RYR2 (rs2485558, replication stage P=0.01, combined P=1.53×10−5), in DPP6 (rs916514,
replication stage P=0.0496, combined P=6.03×10−4), in MMP27 (rs1939015, replication
stage P =0.026, combined P=7.09×10−4) and 31 kb downstream of NFκBIA (rs2145623,
replication stage P=2.29×10−3, combined P =5.01×10−6), respectively (Table 1).
We also confirmed the previously reported association of PsV and the LCE3C-LCE3B
deletion14 at P=3.80×10−5 (for details on genotyping and copy number analyses see Online
Methods).
To further validate the newly associated PsV susceptibility gene TRAF3IP2, we genotyped
the lead SNP, rs13210247, in the two additional case-control panels E (1,987 cases and
1,661 controls from Michigan) and F (1,282 cases and 1,090 controls from Canada). The
combined replication panels B through F comprised 6,015 PsV cases and 6,891 healthy
controls, yielding a replication P value of 1.00×10−7 with the same direction of effect for all
five panels (combined P value for panels A through F=2.36×10−10).
We additionally selected all validated coding SNPs within the TRAF3IP2 gene from NCBI’s
dbSNP16 build 130 (rs1043730, rs13190932 and rs33980500) for genotyping in replication
panel B. Of the existing three missense SNPs, only rs33980500, located in exon 2, showed a
significant association (P=0.0265, OR=1.28, 95% CI=1.03–1.58). Therefore, this SNP was
also genotyped in the replication panels C through F. Association analysis of the obtained
replication cohort (panel B through F) yielded a highly significant P value of 8.00×10−14
(combined P value for panels A through F=1.24×10−16) (Table 2). Because the missense
SNP was not available from the HapMap II CEU imputation reference, we performed
imputation based on CEU haplotypes generated by the 1000 Genomes project for panels A,
C and D in order to fine map a region of 700 kb around TRAF3IP2 containing 1,935 SNPs
(Fig. 1). The intronic TRAF3IP2 SNP rs13210247 and the missense SNP rs33980500 are
about 9.5 kb apart and are in moderate LD (LD in panels A to F; r2=0.63). We performed a
logistic regression analysis to test for the independence of these two markers. When
conditioning for the missense SNP rs33980500, the intronic SNP rs13210247 was not
significantly associated with disease (P=0.709). In the reverse comparison, the missense
SNP rs33980500 remained significantly associated (P=3.77×10−7), indicating that it can
account for the association at the TRAF3IP2 gene locus. In a subset of German cases and
controls (993 cases and 2,277 controls from panels A and B) for which HLA-Cw6 status
was available, we tested for the presence of a statistical interaction between HLA-Cw6
carriership and rs33980500 genotypes but found no statistical support for interaction
(P=0.77).
The missense SNP rs33980500 (Asp19Asn) causes a mutation from aspartic acid to
asparagine in the protein sequence and the resulting change in charge (a negative electric
charge to nonpolar) might have an impact on the protein structure and, hence, its function.
Additionally, the mutation is located in a region that is more than 90% conserved among
different species (Supplementary Fig. 3), which further implies a possible functional
consequence of this change.
Furthermore, we performed in silico analyses and found a putative TRAF6-binding peptide
(amino acids 13 to 21) containing the SNP Asp19Asn. This peptide is similar to a known
TRAF6-binding motif of CD40, a member of the tumor necrosis factor receptor
superfamily17. Notably, the mutation of the accordant seventh peptide residue (asparagine to
aspartate) has previously been observed to change the binding affinity of TRAF6 to CD40
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significantly18. Therefore, rs33980500 may also affect the interaction of TRAF3IP2 to
TRAFs and, thus, the involved inflammatory pathways.
About 15% of individuals with psoriasis develop psoriatic arthritis (PsA), which is an
inflammatory, disabling arthrits2,19. This suggests that PsV and PsA share common
susceptibility factors. To determine the association of the TRAF3IP2 missense SNP with
PsA, we performed a PsA stratified analysis of panel A through F. Association analysis of
all PsA patients and controls within our combined sample (1,919 cases and 8,037 controls)
yielded a P value of 4.57×10−12 for rs33980500 (OR=1.57, CI=1.38–1.78). In an equally
sized subgroup of randomly extracted PsV cases without PsA, we obtained a P value of
2.04×10−6 (OR=1.37, CI=1.20–1.57). The overlap in confidence intervals for the two
associations, along with the fact that no significant difference was obtained when comparing
the 1,919 PsA cases versus the randomly selected 1,919 PsV cases suggests that the
TRAF3IP2 gene locus represents a shared susceptibility locus for PsA and PsV.
Gene expression of psoriatic and uninvolved skin differs significantly for hundreds of genes
that are involved in immune response or in the regulation of cellular differentiation and
proliferation20. To check if altered gene activity might trigger disease progression, we
examined expression levels of several loci in biopsies from 57 healthy controls and
compared these to expression levels of biopsies of involved and uninvolved skin from 53
PsV cases (subgroup of panel C). We analyzed the TRAF3IP2 locus and some genes that
potentially act downstream of TRAF3IP2. For the TRAF3IP2 locus, the expression level was
slightly altered between involved and uninvolved skin (P=2.2×10−3) (Supplementary Fig.
4). However, the dosage of risk alleles at the according SNPs did not correlate with
transcript levels for the genes in involved, uninvolved or normal skin (Supplementary Table
3).
Genetic variants in the TRAF3IP2 locus are implicated in PsV and PsA susceptibility for the
first time, to our knowledge, by our study. The gene product of TRAF3IP2 is a positive
signaling adaptor required for IL-17-mediated T-cell immune responses21. The TRAF3IP2
protein interacts with tumor necrosis factor receptor-associated factor (TRAF) proteins and
either I-κB kinase or mitogen-activated protein kinase to activate either NF-κB or Jun
kinase. Upon recruitment to CD40 and the BAFF receptor in B-cells, TRAF3IP2 also
negatively regulates B-cell survival through its interaction with TRAF322. The negative
regulation of CD40-BAFF-mediated B cell functions results in ‘hyper-T cell-dependent’ and
T cell-independent immune responses in TRAF3IP2-deficient mice. Researchers in a
previous study also found that TRAF3IP2 is a key component of IL-17-mediated signaling
and that IL-17-mediated gene expression is completely abolished in TRAF3IP2-deficient
mouse embryonic fibroblasts. In addition, epithelial cells could be identified as the critical
cell type in which TRAF3IP2 mediates IL-17-dependent inflammatory disease21. In PsV, a
subset of T-cells expressing IL-17 plays a major role23. The IL-17 expressing T-cells that
are abundant in the epidermis of psoriatic lesions but which are absent in healthy donor
epidermis are CD8+ cells, whereas in lesional psoriatic dermis, mainly IL-17 expressing
CD4+ (but also CD8+) T-cells are strongly increased relative to healthy skin. Epidermal
hyperplasia and the production of innate immune peptides such as human β-defensin 2
(hBD-2) are associated with these IL-17+ T-cells24. The crucial role of IL-17 is also
supported by the observation that in psoriasis treatment response to TNF inhibitors
correlates with suppressed IL-17 signaling25. Moreover, we showed that in immortalized N-
TERT keratinocytes (N-TERT KCs) and in normal human keratinocytes (NHKs) IL-17A
and TNF-α together induce the expression of DEFB4 (encoding hBD-2) which is absent in
N-TERT KCs and NHKs with silenced TRAF3IP2 (see Supplementary Fig. 5). In epithelial
cells, the binding of IL-17A and/or IL-17F to the heterodimeric IL-17R leads to the
recruitment of TRAF3IP2 through homotypic interactions between conserved (SEFIR)
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domains. This allows the incorporation of TRAF6 into the signaling complex and then
downstream activation of the NF-κB and mitogen-activated protein kinase pathways26. We
thus speculate that a dysregulation of TRAF3IP2 might have a major impact on IL-17
signaling and, hence, on the activation of NFκB-pathways, leading to the upregulation of
pro-inflammatory factors.
For the TRAF3IP2 locus newly identified here, fine mapping and resequencing efforts
together with extensive functional studies are required to detect all potential causal variants
and thus to specify the contribution of the locus to overall disease susceptibility.
Online Methods
Recruitment of patients and healthy controls
Samples were organized in panels that corresponded to the successive steps of the present
study. All individual panels (A–F) were independent from each other. All German patients
of panels A and B were recruited either at the Department of Dermatology of the Christian-
Albrechts-University Kiel or the Department of Dermatology and Allergy of the Technical
University Munich through local outpatient services. Individuals were considered to be
affected if chronic plaque or guttate psoriasis lesions covered more than 1% of the total body
surface area or if at least two skin, scalp, nail or joint lesions were clinically diagnosed of
psoriasis. Psoriatic arthritis (PsA) was diagnosed by clinical finding of joint complaints and
radiologic and rheumatologic confirmation by criteria according to Moll and Wright27, or
more recently to the Classification Criteria for Psoriatic Arthritis (CASPAR)28.
2510 German healthy control individuals of panel A and B were obtained from the popgen
biobank29. 483 German healthy controls were selected from the KORA S4 survey, an
independent population-based sample from the general population living in the region of
Augsburg, southern Germany30.
The American study population (panel C) consisted of 1303 psoriasis cases and 1322
controls after quality control. The data sets used for the analyses described in this
manuscript were obtained from the database of Genotype and Phenotype (dbGaP). The
genotyping of samples was provided through the Genetic Association Information Network
(GAIN). Samples and associated phenotype data were provided by the “Collaborative
Association Study of Psoriasis” (CASP). Funding support for CASP was provided by the
National Institutes of Health, the Foundation for NIH’s Genetic Association Information
Network and the National Psoriasis Foundation.
The Canadian population sample used for panel D consisted of 762 psoriasis patients and
994 controls, sampled from the Québec founder population (QFP). Membership in the QFP
was defined as having four grandparents with French-Canadian family names who were
born in the Province of Québec, Canada, or in adjacent areas of the Provinces of New
Brunswick and Ontario or in New England or New York State. This criterion assures that all
subjects were descendant from French-Canadians living before the 1960s, after which time
admixture with non-French-Canadians became more common.
For replication of the two TRAF3IP2 SNPs (rs13210247 and rs33980500), panel E was
tested in addition for an association. This panel comprised 1987 psoriasis cases and 1661
controls of European ancestry. The sample was collected at the University of Michigan and
selection criteria for cases included a requirement of at least two psoriatic plaques or a single
plaque occupying >1% of total body surface area outside scalp. Individuals that presented
only palmoplantar psoriasis, inverse psoriasis or sebopsoriasis were excluded. Individuals
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used as controls were older than 18 years, had no history of psoriasis and no family history
of psoriasis.
Panel F, also used only for replication of the two TRAF3IP2 SNPs, consisted of 1282
psoriasis cases and 1090 controls from Toronto and Newfoundland, Canada. Psoriasis was
diagnosed by a dermatologist. Control individuals showed no evidence of psoriasis,
rheumatoid arthritis or other auto-immune disorders.
Written, informed consent was obtained from all study participants and all protocols were
approved by the respective institutional ethical review committees of the participating
centres.
SNP genotyping for genome-wide screen
The genotyping for the GWAS - which was part of the German GWAS initiative funded by
the National Genome Research Network (NGFN) - was performed by Illumina’s service
facility (San Diego, CA, USA) using the Illumina HumanHap 550k v1 with 561,466 SNP
markers (San Diego, CA, USA). All experimental steps were carried out according to
standard protocols.
We excluded 5 samples with more than 10% missing genotypes (i.e. call rate <90%).
Individuals who showed statistically relevant genetic dissimilarity to the other subjects
(population outliers), or who showed evidence for cryptic relatedness to other study
participants (unexpected duplicates, first- or second-degree relatives) were removed
(Supplementary Fig. 1). These quality control measures left 472 psoriasis samples and 1146
control samples for inclusion in screening panel A. All gender assignments could be verified
by reference to the proportion of heterozygous SNPs on the X chromosome. Before analysis
we excluded 56,724 markers (10% of all SNPs) that had a low genotype call rate (<95% in
cases or controls; n=4,254), were monomorphic or rare (minor allele frequency <2% in cases
or controls; n=30,862), deviated from Hardy-Weinberg equilibrium (HWE) in the control
sample (PHWE<0.01; n=7,600), or that were non-autosomal SNPs (n=14,008).
Imputation
Genotype imputation was performed using a hidden Markov model algorithm implemented
in the software program MACH v.1.0.1631 to infer missing genotypes in silico. As a
reference, HapMap II CEU phased haplotypes32 were used.
As input for the imputation only genotyped SNPs that passed quality control were used. Of
the imputed SNPs we analyzed only these SNPs which could be imputed with a relatively
high confidence (estimated r2 between imputed SNP and true genotypes ≥0.8), had a minor
allele frequency >2% in cases or controls and a HWE P-value <0.01 in the control sample.
To take imputation uncertainty into account, we used allelic dosage association as
implemented in the program MACH2DAT31. The allelic dosage is the weighted sum of the
genotype class probabilities.
SNP selection for replication
SNPs of the genome-wide scan that passed quality control were analyzed using gPLINK
v2.049 in combination with PLINK v1.0533. The SNP list (including imputed and genotyped
SNPs) was pruned for redundancy due to linkage disequilibrium by using the --clump
command of PLINK. For all genotyped index SNPs with a P-value <10−3, a visual
inspection of the cluster plots was performed. SNPs that did not pass the visual inspection
were excluded from further analyses. The 180 most strongly associated index SNPs of the
clumps (P<2.6×10−4) were ordered as genotyping assays. If the genotyping assay design
Ellinghaus et al. Page 7













was not possible for a SNP, the next best SNP from the clump was chosen for the assay
design.
SNPlex and TaqMan genotyping
The ligation-based SNPlex™ genotyping system and functionally tested TaqMan® SNP
Genotyping Assays (Applied Biosystems, Foster City, CA, USA) were used to genotype
variants in replication panel B. For technical replication of the results of the two TRAF3IP2
SNPs, TaqMan® SNP Genotyping Assays were used in panels A-E while the Sequenom
Platform was used for panel F.
Of 180 selected SNPs 147 SNPs passed quality control. These SNPs had a high call rate
(>90% in cases or controls; 25 SNPs were removed), were not monomorphic (minor allele
frequency >1% in cases or controls; 2 SNPs were removed), and did not deviate from
Hardy-Weinberg equilibrium (HWE) in the control population (PHWE>0.0001; 5 SNPs were
removed). One SNP failed genotyping and was excluded from the analysis.
CNV genotyping and quality control
The functionally tested TaqMan® Copy Number Assays Hs 02550639_cn (in LCE3C) and
Hs 02878369_cn (in LCE3B) (Applied Biosystems) were used to genotype copy number
variation within the late cornified envelope (LCE) gene cluster in samples of panel A and B
(754 cases and 1052 controls). Genotyping was carried out according to Applied Biosystems
standard protocols with 5ng of dried DNA per well.
All cases were genotyped thrice and all control samples were genotyped four times. The
generated data was analyzed with the analysis software CopyCaller™ v1.0. The analysis
settings were selected as recommended by the CopyCaller™ Software User Guide. The
chosen confidence threshold of the associated predicted copy number was ≥95%. Control
samples were removed when more than one of the four measurements did not pass quality
control whereas cases were removed when one of the three measurements did not pass
quality control. Altogether, 736 cases and 932 controls remained for association analysis
(94% of all samples).
Statistical analyses
Power calculations were carried out using PS Power and Sample Size v3.0.1234. GWAS
data were analyzed using R statistical environment version 2.10.0 and gPLINK v2.049 in
combination with PLINK v1.0533. The --clump command was used to reduce the number of
SNPs for follow-up by removing correlated hit SNPs. The meta-analysis of the different
panels was performed with METAL.
TRAF3IP2 silencing in keratinocytes
Small hairpin RNA (shRNA) targeting enhanced green fluorescent protein (EGFP) was
cloned into the pLenti4/Block-iT-DEST (Invitrogen, Carlsbad, CA) as previously
described35. ShRNA lentiviral constructs directed against TRAF3IP2 were obtained from
Sigma (St. Louis, MO). Lentiviral particles were produced in 293FT cells and used to infect
immortalized N-TERT keratinocytes (kindly provided by Dr. James Rheinwald) and normal
human keratinocytes (NHK) at 10–20% percent confluence as previously described36. After
72 h of infection the cells were incubated in basal medium and stimulated for 30 h with IL17
(10 ng/ml), IL22 (10 ng/ml) and/or TNF-α (20 ng/ml). Total RNA was isolated using
RNeasy Mini Kits with on-column DNAse digestion according to the manufacturer’s
instructions (Qiagen, Valencia, CA) and reversed transcribed using the High Capacity
cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA). Real-time PCR
analysis for DEFB4, TRAF3IP2 and the control gene RPLP0 (ribosomal protein P0) was
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performed using pre-validated TaqMan gene expression assays from Applied Biosystems
according to the manufacturer’s instructions. Target gene expression was normalized to the
control gene RPLP0 and mRNA levels were expressed as percent of RPLP0.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Regional plot of TRAF3IP2
Regional plot of the negative decadic logarithm of the combined P values from the imputed
panels A, C and D in a ~700 kb window around the intronic lead SNP rs13210247 (blue
filled diamond) and the missense SNP rs33980500 (r2=0.63). Panels A, C and D were
imputed with CEU haplotypes generated by the 1000 Genomes Project (August 2009
release) as a reference. The intronic SNP rs13210247 and the missense SNP rs33980500
were genotyped in the replication panels, and the combined P values of panels A through F
are indicated for both SNPs (Table 2). The magnitude of linkage disequilibrium (LD) with
the central SNP rs13210247, measured by r2, is reflected by the color of each SNP symbol
(for color coding, see upper right corner of each plot). Recombination activity (cM/Mb) is
depicted by a blue line.
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